Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Gain Therapeutics (GANX)
NASDAQ:GANX
Holding GANX?
Track your performance easily
GANX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.89 - $5.33
Previous Close$1.48
Volume145.56K
Average Volume (3M)355.45K
Market Cap
$38.18M
Enterprise Value$21.66M
Total Cash (Recent Filing)$16.94M
Total Debt (Recent Filing)$807.57K
Price to Earnings (P/E)―
Beta1.19
Next Earnings
Nov 08, 2024EPS Estimate
-$0.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.31
Shares Outstanding25,535,460
10 Day Avg. Volume258,467
30 Day Avg. Volume355,452
Standard Deviation0.17
R-Squared0.00974
Alpha-0.05
Financial Highlights & Ratios
Price to Book (P/B)1.57
Price to Sales (P/S)691.84
Price to Cash Flow (P/CF)-1.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit392.60
Enterprise Value/Ebitda-1.01
Forecast
1Y Price Target
$7.75Price Target Upside418.39% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Gain Therapeutics News
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessThe Phase 1 study enrolled 72 healthy volunteers, males and females, up to the age of 64 years, confirming that single and multiple doses of GT-02287 were safe and generally well tolerated up to and including the highest planned dose levels across all age groups.
Financial StabilityGain Therapeutics ended 2Q24 with $16.9M in cash and cash equivalents, following the completion of an equity offering that yielded roughly $10M in net proceeds.
Target Engagement AchievementThe favorable safety and tolerability profile at oral dose levels that resulted in therapeutic plasma levels, CNS exposure, and target engagement further strengthens GT-02287’s potential to be a lead treatment for Parkinson’s disease (PD).
Bears Say
Clinical TrialsDelays in advancing preclinical candidates into clinical studies could negatively impact the stock.
Financial PerformanceThe company recorded a net loss of $0.42 per share, significantly higher than the forecasted net loss of $0.21 per share, due to substantially higher-than-projected operating expenses.
Stock DilutionRecent financing has led to dilution, resulting in a lowered 12-month price target from $9 to $8.
---
Ownership Overview
5.09% Insiders
1.44% Mutual Funds
9.91% Other Institutional Investors
83.56% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
GANX FAQ
What was Gain Therapeutics’s price range in the past 12 months?
Gain Therapeutics lowest stock price was $0.89 and its highest was $5.33 in the past 12 months.
What is Gain Therapeutics’s market cap?
Currently, no data Available
When is Gain Therapeutics’s upcoming earnings report date?
Gain Therapeutics’s upcoming earnings report date is Nov 08, 2024 which is in 49 days.
How were Gain Therapeutics’s earnings last quarter?
Gain Therapeutics released its earnings results on Aug 08, 2024. The company reported -$0.42 earnings per share for the quarter, missing the consensus estimate of -$0.195 by -$0.225.
Is Gain Therapeutics overvalued?
According to Wall Street analysts Gain Therapeutics’s price is currently Undervalued.
Does Gain Therapeutics pay dividends?
Gain Therapeutics does not currently pay dividends.
What is Gain Therapeutics’s EPS estimate?
Gain Therapeutics’s EPS estimate is -$0.21.
How many shares outstanding does Gain Therapeutics have?
Gain Therapeutics has 25,535,460 shares outstanding.
What happened to Gain Therapeutics’s price movement after its last earnings report?
Gain Therapeutics reported an EPS of -$0.42 in its last earnings report, missing expectations of -$0.195. Following the earnings report the stock price went up 2.105%.
Which hedge fund is a major shareholder of Gain Therapeutics?
Among the largest hedge funds holding Gain Therapeutics’s share is Greenlight Capital Inc. It holds Gain Therapeutics’s shares valued at 753K.
---
Gain Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.75 (418.39% Upside)
$7.75 (418.39% Upside)
Blogger Sentiment
Bullish
GANX Sentiment 100%
Sector Average 71%
Sector Average 71%
Insider Transactions
Bought Shares
Worth $84.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.7%
Last 30 Days ▲ 8.4%
Last 30 Days ▲ 8.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-58.19%
12-Months-Change
Fundamentals
Return on Equity
-188.83%
Trailing 12-Months
Asset Growth
5.12%
Trailing 12-Months
Company Description
Gain Therapeutics
Gain Therapeutics Inc is a development-stage biotechnology company developing novel therapeutics to treat diseases caused by protein misfolding, with an initial focus on lysosomal storage disorders (LSDs), including rare genetic diseases and neurological disorders. Its pipeline includes the GLB1 gene, GBA1 gene, IDUA gene, and GALC gene.
---
GANX Stock 12 Month Forecast
Average Price Target
$7.75
▲(418.39% Upside)
Technical Analysis
Best Analysts Covering GANX
1 Year
1 Year Success Rate
2/9 ratings generated profit
1 Year Average Return
-33.82%
reiterated a buy rating 17 days ago
Copying Jason McCarthy's trades and holding each position for 1 Year would result in 22.22% of your transactions generating a profit, with an average return of -33.82% per trade.
---